The lupus anticoagulant was found in the plasma of 31 of 60 patients with systemic lupus erythematosus and other connective tissue disorders
Introduction
A clotting defect due to the so called "lupus anticoagulant" in the plasma of patients with systemic lupus erythematosus was first recognised by Conley and Hartmann in 19521 but the first case report was probably that of Aggeler, Lindsay, and Lucia in 1946. 2 Since then it has become apparent that the lupus anticoagulant is an antibody3 that is a prothrombinase complex inhibitor. 4 In vitro the presence of the lupus anticoagulant is characterised by a prolonged kaolin partial thromboplastin time. Paradoxically, in vivo it appears to have a hypercoagulable effect. 6 We studied 60 patients with systemic lupus erythematosus and other connective tissue disorders. Clinical and serological findings in these patients were related to the presence or absence of lupus anticoagulant.
Materials and methods
Forty nine patients with systemic lupus erythematosus and 11 patients with other connective tissue disorders were studied. All the patients with systemic lupus erythematosus fulfilled the revised criteria of the American Rheumatism Association.7 Of the 11 patients with other connective tissue disorders, four had mixed connective tissue disease, two systemic vasculitis, and one each of polyarteritis nodosa, primary sicca syndrome, discoid lupus, Behqet 
Results

AGE AND DURATION OF DISEASE
The mean age at follow up was 32-7 years (range 13-59). Mean age of onset of symptoms was 25-9 years and the duration of symptoms was 5 4 years.
SEROLOGY
A total of 31 of the 60 patients (26 female and five male) were found to have the lupus anticoagulant activity; 25 ofthese had systemic lupus erythematosus. Biological false positive seroreaction for syphilis was present in seven patients out of 60 and all seven had lupus anticoagulant activity (table I): the association was significant (p < 0 05).
Increased titres of antibodies to DNA were present in 11 patients with lupus anticoagulant activity and in 16 without the activity. No association was found with increased DNA binding or the presence of antibodies to extractable nuclear antigen could be shown (table I) .
Plasma samples of eight patients were fractionated, and the immunoglobulin fractions were tested for the lupus anticoagulant activity. Five of the eight patients were receiving warfarin. The activity resided in the IgG fraction in all eight patients and in both the IgG and IgM fractions in four. Central nervous system disease, as defined by neuropsychiatric manifestations or cerebrovascular accidents, was present in 17 patients with the lupus anticoagulant and in 10 without. No significant correlation was found between the two groups of patients. Catterall reported the association of chronic biologically false positive reaction to the tests for syphilis and "lupoid sclerosis" in six young women who presented with symptoms and signs of a neurological disorder resembling multiple sclerosis.9 In our present study no patient had evidence of demyelinating disease, although dementia was present in two patients with biological false positive reactions.
Four patients with the lupus anticoagulant had pulmonary hypertension confirmed by right heart catheter studies; this could be more than a chance association.
Discussion
Thrombosis has long been recognised as a complication of systemic lupus erythematosus.10 In addition to the occurrence of leg vein thrombosis in up to 15%' of patients with systemic lupus erythematosus,' thrombosis in renal, retinal, cerebral, and pulmonary veins are well recognised.'2 In this study we have extended earlier observations and shown a highly significant association between the presence of thrombotic complications in systemic lupus erythematosus and related connective tissue disorders and the presence of the lupus anticoagulant.
The lupus anticoagulant is an acquired inhibitor of the prothrombin complex (factor Xa, factor V, and phospholipid).4 6 It has been shown in patients with systemic lupus erythematosus and in a heterogeneous group of patients." It appears to have a specific antiphospholipid activity against the phospholipid portion of the prothrombin activator complex.'4 15 In our study 49 of 60 patients had systemic lupus erythematosus. We confirmed the association between the lupus anticoagulant and the high incidence of another antibody with phospholipid specificity, a biological false positive reaction for syphilis.", 17 The antibody nature of the lupus anticoagulant has been shown, and is in agreement with the findings of other investigations3' 18: it is characterised as IgG or IgM or a mixed IgG and IgM.
A very strong association between the lupus anticoagulant and clotting defect was noted in our patients. The presence of the anticoagulant may play a critical but as yet unclear part in the activation of the coagulation system in the complex mechanism of immune disorder. It has been suggested that by its reaction with phospholipid in platelets it could cause cellular damage by interference with release of arachidonic acid, the substrate for production of prostacyclin, which is a physiological inhibitor of platelet aggregation. This vascular endothelial cell injury results in lowered prostacyclin concentrations and this may predispose to thrombosis.' 9 2 0 The presence of lupus anticoagulant appears to define a subset of patients with recurrent abortions2" and thrombocytopenia. Although a high fetal wastage has been recognised in women with systemic lupus erythematosus, the exact cause is unclear. The significant association with the lupus anticoagulant, an antibody, adds evidence to the immunological mechanism for spontaneous abortion in systemic lupus erythematosus. The thrombocytopenia could result from antiphospholipid activity of the lupus anticoagulant on platelets. The lack of haemorrhagic tendencies is unexplained and the relation between thrombocytopenia and thrombosis is unknown.
The varied associations of the lupus anticoagulant shown in our study have practical relevance in the management of patients. Administration of steroids may result in reduction or disappearance of the anticoagulant activity.5 22 The lupus anticoagulant disappeared in one of our patients after plasmapheresis and in another after pulse immunosuppressive treatment for his primary disease. We suggest that the detection and measurement of the lupus anticoagulant could serve both as a marker of disease and in the assessment of disease activity in the follow up of patients.
Finally Of the 25 patients with hepatomegaly or jaundice, 23 (92%) died within three months. Necropsy was performed in four patients who died early; in -each the liver was almost completely replaced by tumour deposits. In contrast, laparotomy in three of the longer term survivors showed peritoneal seedlings without evidence of liver metastases. The usefulness of hepatomegaly or jaundice as a prognostic factor is not altered by additional information on previous skin metastasis.
Various treatments-were used among both short and longer term survivors. This suggests that it is hepatic metastases rather than any particular treatment that determines survival.
Comment
These findings may have implications for the management of patients with -ascites secondary to breast cancer. Of those patients who have associated hepatomegaly or jaundice, 90% will be dead within three months, probably as a result of liver failure, and will gain no benefit from active local treatment of their ascites. In contrast, the longer term survivors will emerge from those patients in whom hepatomegaly and jaundice are absent. These patients with supposed peritoneal metastases may benefit from local treatment provided that they have adequate hepatic function, as assessed by radioisotopic scanning and blood biochemistry tests, and do not have overt disease elsewhere requiring systemic treatment.
Each of the longer term survivors was treated empirically, and ascites -was controlled in one third of cases. A similar response rate would be predicted for patients with advanced breast cancer given endocrine treatment-or cytotoxic chemotherapy. We do not know whether specific local treatment such as intracavitary adriamycin3 or peritoneovenous shunts4 gives any greater benefit than systemic treatment alone. A multicentre controlled trial would be needed to answer this question. 
